129 related articles for article (PubMed ID: 29552172)
21. NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation.
Sun Z; Li Q; Zhang S; Chen J; Huang L; Ren J; Chang Y; Liang Y; Wu G
Onco Targets Ther; 2015; 8():269-77. PubMed ID: 25674002
[TBL] [Abstract][Full Text] [Related]
22. Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells.
Yu Y; Yu X; Ma J; Tong Y; Yao J
Int J Oncol; 2016 Jul; 49(1):285-93. PubMed ID: 27176231
[TBL] [Abstract][Full Text] [Related]
23. Effect of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against human Merkel cell carcinoma MKL-1 cells.
Lin Z; Mei H; Fan J; Yin Z; Wu G
Oncol Lett; 2015 Dec; 10(6):3663-3667. PubMed ID: 26788188
[TBL] [Abstract][Full Text] [Related]
24. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
25. Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule.
Kuger S; Graus D; Brendtke R; Günther N; Katzer A; Lutyj P; Polat B; Chatterjee M; Sukhorukov VL; Flentje M; Djuzenova CS
Transl Oncol; 2013 Apr; 6(2):169-79. PubMed ID: 23544169
[TBL] [Abstract][Full Text] [Related]
26. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Kirstein MM; Boukouris AE; Pothiraju D; Buitrago-Molina LE; Marhenke S; Schütt J; Orlik J; Kühnel F; Hegermann J; Manns MP; Vogel A
Liver Int; 2013 May; 33(5):780-93. PubMed ID: 23489999
[TBL] [Abstract][Full Text] [Related]
27. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
Li JR; Cheng CL; Yang CR; Ou YC; Wu MJ; Ko JL
Toxicol Lett; 2013 Jul; 220(3):267-76. PubMed ID: 23651616
[TBL] [Abstract][Full Text] [Related]
28. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
Kudoh A; Oishi T; Itamochi H; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895
[TBL] [Abstract][Full Text] [Related]
29. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.
Hernlund E; Olofsson MH; Fayad W; Fryknäs M; Lesiak-Mieczkowska K; Zhang X; Brnjic S; Schmidt V; D'Arcy P; Sjöblom T; De Milito A; Larsson R; Linder S
Eur J Cancer; 2012 Feb; 48(3):396-406. PubMed ID: 22154651
[TBL] [Abstract][Full Text] [Related]
30. NVP-BEZ235-induced autophagy as a potential therapeutic approach for multiple myeloma.
Ma Y; Jin Z; Yu K; Liu Q
Am J Transl Res; 2019; 11(1):87-105. PubMed ID: 30787971
[TBL] [Abstract][Full Text] [Related]
31. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
Schnell CR; Stauffer F; Allegrini PR; O'Reilly T; McSheehy PM; Dartois C; Stumm M; Cozens R; Littlewood-Evans A; García-Echeverría C; Maira SM
Cancer Res; 2008 Aug; 68(16):6598-607. PubMed ID: 18701483
[TBL] [Abstract][Full Text] [Related]
32. The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway.
Luo H; Yu YY; Chen HM; Wu W; Li Y; Lin H
Exp Ther Med; 2019 Jan; 17(1):99-106. PubMed ID: 30651769
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
34. NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma.
Huang JC; Cui ZF; Chen SM; Yang LJ; Lian HK; Liu B; Su ZH; Liu JS; Wang M; Hu ZB; Ouyang JY; Li QC; Lu H
Oncotarget; 2018 Feb; 9(12):10483-10496. PubMed ID: 29535821
[TBL] [Abstract][Full Text] [Related]
35. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
[TBL] [Abstract][Full Text] [Related]
36. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
Matsushima M; Kikuchi E; Matsumoto K; Hattori S; Takeda T; Kosaka T; Miyajima A; Oya M
Int J Oncol; 2015 Jul; 47(1):377-83. PubMed ID: 25963317
[TBL] [Abstract][Full Text] [Related]
37. Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response.
Xie G; Wang Z; Chen Y; Zhang S; Feng L; Meng F; Yu Z
Cancer Lett; 2017 Mar; 388():12-20. PubMed ID: 27894954
[TBL] [Abstract][Full Text] [Related]
38. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Marone R; Erhart D; Mertz AC; Bohnacker T; Schnell C; Cmiljanovic V; Stauffer F; Garcia-Echeverria C; Giese B; Maira SM; Wymann MP
Mol Cancer Res; 2009 Apr; 7(4):601-13. PubMed ID: 19372588
[TBL] [Abstract][Full Text] [Related]
39. Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat.
Ren XS; Sato Y; Harada K; Sasaki M; Furubo S; Song JY; Nakanuma Y
PLoS One; 2014; 9(1):e87660. PubMed ID: 24498161
[TBL] [Abstract][Full Text] [Related]
40. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
